Showing results (1-10 of 77) with videos related to
Sort By:
Pageof 8
Molecules (Basel, Switzerland)|July 27, 2022
Anticancer InhibitorsAlessandra Ammazzalorso, Marialuigia FantacuzziBiology|January 21, 2022
PPAR Ligands Induce Antiviral Effects Targeting Perturbed Lipid Metabolism during SARS-CoV-2, HCV, and HCMV InfectionMarialuigia Fantacuzzi, Rosa Amoroso, Alessandra AmmazzalorsoExpert Opinion on Therapeutic Patents|March 19, 2024
Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020-2023)Barbara De Filippis, Arianna Granese, Alessandra AmmazzalorsoExpert Opinion on Therapeutic Patents|April 29, 2024
Recent trends and challenges to overcome Pseudomonas aeruginosa infectionsAlessandra Ammazzalorso, Arianna Granese, Barbara De FilippisInternational Journal of Molecular Sciences|November 25, 2023
Anticancer Activity of Natural Products and Related CompoundsBarbara De Filippis, Marialuigia Fantacuzzi, Alessandra AmmazzalorsoEuropean Journal of Medicinal Chemistry|April 23, 2019
Multitarget PPARγ agonists as innovative modulators of the metabolic syndromeAlessandra Ammazzalorso, Cristina Maccallini, Pasquale Amoia, et al.Expert Opinion on Drug Discovery|July 4, 2019
Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?Paolo Guglielmi, Simone Carradori, Alessandra Ammazzalorso, et al.European Journal of Medicinal Chemistry|September 8, 2020
2-substituted benzothiazoles as antiproliferative agents: Novel insights on structure-activity relationshipsAlessandra Ammazzalorso, Simone Carradori, Rosa Amoroso, et al.Chemmedchem|August 14, 2013
Blocking the peroxisome proliferator-activated receptor (PPAR): an overviewAlessandra Ammazzalorso, Barbara De Filippis, Letizia Giampietro, et al.Molecules (Basel, Switzerland)|April 3, 2021
Development of CDK4/6 Inhibitors: A Five Years UpdateAlessandra Ammazzalorso, Mariangela Agamennone, Barbara De Filippis, et al.Pageof 8